Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cocaine abuse vaccine TA-CD

Drug Profile

Cocaine abuse vaccine TA-CD

Alternative Names: TA-CD; TA-CD09

Latest Information Update: 26 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmuLogic Pharmaceutical
  • Developer Celtic Pharma
  • Class Drug withdrawal therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cocaine abuse

Most Recent Events

  • 31 Aug 2010 Celtic Pharma and the National Institute on Drug Abuse initiate a phase II trial for Cocaine abuse in USA
  • 21 Jun 2006 Interim results from a phase IIb clinical trial in cocaine abuse have been added to the Drug Withdrawal therapeutic trials section
  • 17 Jun 2004 Clinical data from a media release have been added to the Drug Withdrawal immunogenicity and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top